How do these additional substances affect ruxolitinib's mechanism of action?

I can answer this, but I’m missing the key context: which “additional substances” are you referring to?

Ruxolitinib’s mechanism depends on the interaction with JAK signaling. If you share the names of the added substances (or the exact passage/table they come from), I can explain how each one could change ruxolitinib’s activity, for example by:
- altering JAK phosphorylation/STAT signaling (direct pathway modulation),
- competing with ruxolitinib at the same binding site or affecting access to JAKs,
- changing drug metabolism/clearance (e.g., by inducing or inhibiting CYP enzymes),
- affecting drug transport (e.g., efflux/uptake),
- changing immune cell signaling feedback loops (which can shift observed pathway suppression).

Reply with the list of substances (and, if you have it, their concentrations and the experiment/system: cell line, patient data, or in vitro assay), and I’ll map each one to expected mechanistic effects on ruxolitinib’s target pathway.